Add like
Add dislike
Add to saved papers

Utility of MAG3 scintigraphy with the use of a 2 min uptake parameter in the assessment of postsurgical renal transplant complications.

OBJECTIVE: Major complications including acute tubular necrosis or rejection may occur after renal transplantation. We use a semiquantitative parameter, 2 min uptake (2MU), as part of Tc mercaptoacetyltriglycine (MAG3) scintigraphy for transplant evaluation. The aim of this study were (a) to examine the utility of Tc MAG3 scintigraphy in the assessment of postsurgical complications using the renal biopsy as the gold standard and (b) examine for any correlation with 2MU with serum creatinine (sCr) at 3 and 12 months.

MATERIALS AND METHODS: We retrospectively reviewed all Tc MAG3 studies at our institution between July 2015 and June 2016, alongside available renal ultrasound, biopsy, and sCr results.

RESULTS: A total of 105 patients fulfilled the inclusion criteria. 30/105 patients underwent biopsy less than 7 days of the Tc MAG3 study. Within this 7 day cohort, the negative predictive value for rejection with normal perfusion on Tc MAG3 study was 79% and the positive predictive value for rejection with abnormal Tc MAG3 perfusion was 9%. There was a weak negative correlation between 2MU and 3-month sCr (R=-0.358, P<0.001), and 2MU and 12-month sCr (R=-0.348, P<0.001).

CONCLUSION: Although normal perfusion on Tc MAG3 scintigraphy study has a reasonable negative predictive value for rejection, abnormal Tc MAG3 perfusion is not useful in the differentiation of rejection from moderate to severe acute tubular necrosis. The 2MU parameter showed no additional benefit in the identification of rejection, but appeared to have a weak negative correlation with the 3-month and 12-month sCr, and may thus play a role in the prediction of longer term graft function.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app